105 related articles for article (PubMed ID: 16226024)
1. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer.
Randell J; Saarinen A; Walamies M; Vahteristo M; Silvasti M; Lähelmä S
Respir Med; 2005 Dec; 99(12):1485-93. PubMed ID: 16226024
[TBL] [Abstract][Full Text] [Related]
2. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
5. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
[TBL] [Abstract][Full Text] [Related]
6. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma.
Jenkins C; Kolarikova R; Kuna P; Caillaud D; Sanchis J; Popp W; Pettersson E
Respirology; 2006 May; 11(3):276-86. PubMed ID: 16635085
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients.
Singh D; Piccinno A; Borrill Z; Poli G; Acerbi D; Meuleners L; Woodcock A
Pulm Pharmacol Ther; 2008; 21(3):551-7. PubMed ID: 18321744
[TBL] [Abstract][Full Text] [Related]
14. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
[TBL] [Abstract][Full Text] [Related]
15. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
Chuchalin AG; Manjra AI; Rozinova NN; Skopková O; Cioppa GD; Till D; Kaiser G; Fashola T; Kottakis J
J Aerosol Med; 2005; 18(1):63-73. PubMed ID: 15741775
[TBL] [Abstract][Full Text] [Related]
16. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
Molimard M; Till D; Stenglein S; Singh D; Krummen M
Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
[TBL] [Abstract][Full Text] [Related]
17. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline.
Kaae R; Agertoft L; Pedersen S; Nordvall SL; Pedroletti C; Bengtsson T; Johannes-Hellberg I; Rosenborg J
Br J Clin Pharmacol; 2004 Oct; 58(4):411-8. PubMed ID: 15373934
[TBL] [Abstract][Full Text] [Related]
18. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
[TBL] [Abstract][Full Text] [Related]
20. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma.
Lipworth BJ; Sims EJ; Das SK; Morice AH; O'Connor BJ
Ann Allergy Asthma Immunol; 2005 Sep; 95(3):283-90. PubMed ID: 16200820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]